Aptevo reports 86% clinical benefit rate for mipletamig combo in frontline AML, zero CRS

Aptevo Therapeutics Inc.

Mipletamig + venetoclax + azacitidine showed 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients.
79% achieved CR or CRi; 61% achieved CR; 55% of CR/CRi patients reached MRD-negative status.
No cytokine release syndrome (CRS) observed; 35% of responders had high-risk TP53 mutation.
Four patients proceeded to allogeneic stem cell transplant, a rare outcome in older/unfit patients.
Data from RAINIER Phase 1b/2 trial and completed dose expansion trial support safety and tolerability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.